1.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

2.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

3.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

4.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

5.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

1.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

2.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

3.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

4.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

5.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

6.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

7.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

8.

A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care...

1.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

2.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

3.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

4.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

5.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

1.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

2.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

3.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

4.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

5.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

6.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

7.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

8.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

9.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

1.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

2.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

3.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

4.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

5.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

1.

A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventil...

2.

A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventil...

3.

A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventil...

4.

A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventil...

5.

A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventil...